Loading...
Gain Therapeutics, Inc.
GANX•NASDAQ
Healthcare
Biotechnology
$1.50
$-0.07(-4.46%)
Gain Therapeutics, Inc. (GANX) Financial Performance & Income Statement Overview
Review Gain Therapeutics, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-100.00%
↓ 100.00%
Operating Income Growth
8.55%
↑ 8.55%
Net Income Growth
8.34%
↑ 8.34%
Operating Cash Flow Growth
-0.04%
↓ 0.04%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-247.56%
↓ 247.56%
ROIC
-308.42%
↓ 308.42%
Gain Therapeutics, Inc. (GANX) Income Statement & Financial Overview
Review Gain Therapeutics, Inc.'s (GANX) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $20593.00 | $20528.00 |
| Gross Profit | $0.00 | $0.00 | -$20593.00 | -$20528.00 |
| Gross Profit Ratio | $0.00 | |||
| R&D Expenses | $1.22M | $2.62M | $4.44M | $2.50M |
| SG&A Expenses | $2.11M | $1.84M | $3.75M | $1.86M |
| Operating Expenses | $3.33M | $4.46M | $8.18M | $4.36M |
| Total Costs & Expenses | $3.33M | $4.46M | $8.18M | $4.38M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $21307.00 | $21643.00 | $20593.00 | $20528.00 |
| EBITDA | -$3.31M | -$4.44M | -$8.16M | -$4.37M |
| EBITDA Ratio | ||||
| Operating Income | -$3.33M | -$4.46M | -$8.18M | -$4.38M |
| Operating Income Ratio | ||||
| Other Income/Expenses (Net) | $67615.00 | -$15734.00 | $40955.00 | $383380.00 |
| Income Before Tax | -$3.26M | -$4.47M | -$8.14M | -$3.99M |
| Income Before Tax Ratio | ||||
| Income Tax Expense | $504738.00 | $10994.00 | $1209.00 | $19874.00 |
| Net Income | -$3.77M | -$4.49M | -$8.14M | -$4.01M |
| Net Income Ratio | ||||
| EPS | -$0.15 | -$0.17 | -$0.42 | -$0.22 |
| Diluted EPS | -$0.15 | -$0.17 | -$0.42 | -$0.22 |
| Weighted Avg Shares Outstanding | $27.13M | $26.53M | $19.22M | $17.98M |
| Weighted Avg Shares Outstanding (Diluted) | $27.13M | $26.53M | $19.22M | $17.98M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan